Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance
Overview
Authors
Affiliations
Hypoxic and/or anoxic tumor cells can have increased rates of mutagenesis and altered DNA repair protein expression. Yet very little is known regarding the functional consequences of any hypoxia-induced changes in the expression of proteins involved in DNA double-strand break repair. We have developed a unique hypoxic model system using H1299 cells expressing an integrated direct repeat green fluorescent protein (DR-GFP) homologous recombination (HR) reporter system to study HR under prolonged chronic hypoxia (up to 72 h under 0.2% O(2)) without bias from altered proliferation, cell cycle checkpoint activation, or severe cell toxicity. We observed decreased expression of HR proteins due to a novel mechanism involving decreased HR protein synthesis. Error-free HR was suppressed 3-fold under 0.2% O(2) as measured by the DR-GFP reporter system. This decrease in functional HR resulted in increased sensitivity to the DNA cross-linking agents mitomycin C and cisplatin but not to the microtubule-interfering agent, paclitaxel. Chronically hypoxic H1299 cells that had decreased functional HR were relatively radiosensitive [oxygen enhancement ratio (OER), 1.37] when compared with acutely hypoxic or anoxic cells (OER, 1.96-2.61). Using CAPAN1 cells isogenic for BRCA2 and siRNA to RAD51, we confirmed that the hypoxia-induced radiosensitivity was due to decreased HR capacity. Persistent down-regulation of HR function by the tumor microenvironment could result in low-fidelity DNA repair and have significant implications for response to therapy and genetic instability in human cancers.
Development of a near-infrared fluorescent probe for the selective detection of severe hypoxia.
Kasai T, Fujita K, Komatsu T, Ueno T, Kojima R, Hanaoka K RSC Chem Biol. 2025; 6(3):449-456.
PMID: 39911856 PMC: 11791654. DOI: 10.1039/d4cb00243a.
Tumour hypoxia in driving genomic instability and tumour evolution.
Suvac A, Ashton J, Bristow R Nat Rev Cancer. 2025; 25(3):167-188.
PMID: 39875616 DOI: 10.1038/s41568-024-00781-9.
Engineered Cell Microenvironments: A Benchmark Tool for Radiobiology.
Akolawala Q, Accardo A ACS Appl Mater Interfaces. 2025; 17(4):5563-5577.
PMID: 39813590 PMC: 11788991. DOI: 10.1021/acsami.4c20455.
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.
Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .
PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.
Jain A, Barge A, Parris C Oncogene. 2024; 44(4):193-207.
PMID: 39572842 PMC: 11746151. DOI: 10.1038/s41388-024-03227-6.